REPLIMUNE GROUP, INC. Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations
REPLIMUNE GROUP, INC. (REPL) reported Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations of -$928.00 thousand for the 6-month period ending 2018-09-30, per its 10-Q filed 2018-11-14.
Discontinued › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations · last filed 2018-11-14
- REPLIMUNE GROUP, INC. effect of exchange rate on cash and cash equivalents, continuing operations for the quarter ending 2018-06-30 was -$731.00K, a 181.40% decline year-over-year.
- REPLIMUNE GROUP, INC. effect of exchange rate on cash and cash equivalents, continuing operations for the quarter ending 2017-06-30 was $898.00K.
| Period end | Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations 3 month | Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations 6 month |
|---|---|---|
| 2018-09-30 | -$928.00K 10-Q · filed 2018-11-14 | |
| 2018-06-30 | -$731.00K 10-Q · filed 2018-08-30 | |
| 2017-09-30 | $1.49M 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $898.00K 10-Q · filed 2018-08-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |